Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Recruitment Status

Recruiting clinical trials

Status pages show live ClinicalTrials.gov search results by recruitment status, with direct links to official study records plus page-level filtering and sorting.

ClinicalTrials.gov public records Last synced May 21, 2026, 2:23 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official matching trials
13271
Shown on this page
12
Local top conditions
6
Local top sponsors
6
The trial list below is retrieved from the live ClinicalTrials.gov search API for status Recruiting. Results on this page are currently sorted by Recently updated.

Filter and sort this status page

These controls apply only within Recruiting. Default order is Recently updated. Add condition, location, sponsor, or therapy filters to narrow this status page further.

Reset status filters
Clear filters
Showing 1–12 of 13,271 matching trials with status Recruiting.
Indexed local directory records.

Top conditions

Breast Cancer 265 Prostate Cancer 171 Obesity 170 Multiple Myeloma 141 Depression 133 Alzheimer Disease 127

Top sponsors

M.D. Anderson Cancer Center 323 Mayo Clinic 282 National Cancer Institute (NCI) 275 Memorial Sloan Kettering Cancer Center 215 Massachusetts General Hospital 189 VA Office of Research and Development 154

Top locations

New York, New York 2182 Houston, Texas 2038 Boston, Massachusetts 1894 Chicago, Illinois 1441 Los Angeles, California 1376 Philadelphia, Pennsylvania 1343

Top therapies

Pembrolizumab 260 Cyclophosphamide 222 Carboplatin 158 Fludarabine 141 Cisplatin 115 Paclitaxel 110

Indexed official records

Open in full search
Recruiting Not applicable Interventional Accepts healthy volunteers

Word Learning in Bilingual Typical and Late Talking Children: The Role of Meaning and Input

NCT07600242
View directory record Official record
Conditions
Bilingualism, Late Talkers, Network Science, Vocabulary Acquisition
Interventions
Large Semantic Category Condition, Small Semantic Category Condition
Behavioral
Lead sponsor
Boston University Charles River Campus
Other
Eligibility
24 Months to 30 Months
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2029
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced May 21, 2026, 2:23 AM EDT
Recruiting Phase 4 Interventional

Mavacamten to Aficamten Transition in Patients With Obstructive Hypertrophic Cardiomyopathy

NCT07600177
View directory record Official record
Conditions
Hypertrophic Cardiomyopathy (HCM)
Interventions
Aficamten
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 90 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
2
States / cities
Kansas City, Missouri • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced May 20, 2026, 1:33 PM EDT
Recruiting Not applicable Interventional

Speech Amplification Devices for Parkinson Disease: Talker- and Technology-Driven Enhancements

NCT07599696
View directory record Official record
Conditions
Atypical Parkinsonism, Parkinson Disease
Interventions
Behavioral speech strategies + speech amplification
Behavioral
Lead sponsor
Michigan State University
Other
Eligibility
50 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
East Lansing, Michigan
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced May 21, 2026, 1:52 AM EDT
Recruiting Early Phase 1 Interventional

Open Label Study for the Use of Low Intensity Focused Ultrasound for Essential Tremor

NCT07599592
View directory record Official record
Conditions
Essential Tremor
Interventions
Low Intensity Focused Ultrasound (LIFU)
Device
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years to 90 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced May 20, 2026, 8:15 AM EDT
Recruiting Phase 1Phase 2 Interventional

Partial Stem Cell Transplant for Sickle Cell Disease From Matched Donors

NCT07599176
View directory record Official record
Conditions
Beta-thalassemia, Sickle Cell Disease
Interventions
Abatacept, Alemtuzumab, Research blood draw, Total Body Irradiation
Drug · Other · Radiation
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
4 Years to 65 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2035
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced May 20, 2026, 7:27 PM EDT
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

Sensory Feedback and Hand Motor Adaptation

NCT07598695
View directory record Official record
Conditions
Stroke
Interventions
Visual ROM augmentation, Visual ROM reduction
Device
Lead sponsor
The Catholic University of America
Other
Eligibility
20 Years to 70 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced May 20, 2026, 11:43 AM EDT
Recruiting Phase 2 Interventional

Modulation of the Immune System in Down Syndrome for Improved Outcomes and Neurodevelopment - 1

NCT07598643
View directory record Official record
Conditions
Down Syndrome
Interventions
Placebo, Tofacitinib Oral Solution
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
6 Years to 22 Years
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced May 20, 2026, 8:44 AM EDT
Recruiting Phase 2Phase 3 Interventional

Surabgene Lomparvovec Administered in the Suprachoroidal Space in Adult Participants With Diabetic Retinopathy Without Center-Involved Diabetic Macular Edema

NCT07592273
View directory record Official record
Conditions
Diabetic Retinopathy
Interventions
Artificial Tears, Sham, Surabgene Lomparvovec, Topical Steroid
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
576 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2036
U.S. locations
2
States / cities
Oak Forest, Illinois • Austin, Texas
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced May 20, 2026, 11:56 PM EDT
Recruiting Phase 2 Interventional

Intra-Articular Allocetra in Patients With Primary Knee Osteoarthritis

NCT07580716
View directory record Official record
Conditions
Primary Knee Osteoarthritis
Interventions
Allocetra, Placebo
Drug · Other
Lead sponsor
Enlivex Therapeutics Ltd.
Industry
Eligibility
64 Years and older
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
4
States / cities
Longwood, Florida • Miami, Florida • New Orleans, Louisiana + 1 more
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced May 20, 2026, 8:57 AM EDT
Recruiting No phase listed Observational

At-Home Bowel Stimulation

NCT07574437
View directory record Official record
Conditions
Post-Operative Ileus (POI)
Interventions
At-home bowel stimulation
Other
Lead sponsor
The Cleveland Clinic
Other
Eligibility
18 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Weston, Florida
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced May 20, 2026, 1:10 PM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

A Study to Evaluate Safety and Efficacy of TP-05 in Healthy Participants With Tick Exposure

NCT07562087
View directory record Official record
Conditions
Lyme Disease
Interventions
Placebo, TP-05 (lotilaner) High Dose, TP-05 (lotilaner) Low Dose
Drug
Lead sponsor
Tarsus Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
700 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
19
States / cities
Pikesville, Maryland • Brookline, Massachusetts • Fall River, Massachusetts + 16 more
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced May 20, 2026, 11:35 PM EDT
Recruiting Phase 1 Interventional

Tirzepatide s Dopaminergic Effects in Alcohol Use Disorders (AUD)

NCT07559500
View directory record Official record
Conditions
Alcohol Use Disorder (AUD)
Interventions
Placebo, Tirzepatide, [11C]NNC-112, [11C]raclopride plus drug
Drug
Lead sponsor
National Institute on Alcohol Abuse and Alcoholism (NIAAA)
NIH
Eligibility
21 Years to 65 Years
Enrollment
176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced May 21, 2026, 12:34 AM EDT